- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07577947
Health And Response: Digital Markers for Outcomes in Perinatal Depression Treatment Study (HARMONY)
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Eliza Congdon, PhD
- Telefoonnummer: (310)-339-9053
- E-mail: harmonystudy@mednet.ucla.edu
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- University of California, Los Angeles
-
Hoofdonderzoeker:
- Nelson Freimer, MD
-
Contact:
- Eliza Congdon
- Telefoonnummer: (310)-339-9053
- E-mail: harmonystudy@mednet.ucla.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- At least 18 years of age
- Able to read and communicate in English
- Between 28 weeks pregnant and 12 weeks postpartum
- Moderate-to-severe depression, as defined by Edinburgh Postnatal Depression Scale (EPDS) score ≥11
- Not currently seeing a provider for mental health care
- Own functioning iOS smartphone (iPhone 11 or newer, iOS 18 or newer) with access to reliable data plan and Wifi)
- Able to read and understand a written informed consent form
- Willingness to participate in treatment through the study and follow all study procedures, including providing HIPAA Authorization for research, installing a study app on personal iPhone, and wearing the provided Apple Watch for at least 20 hours every day in the first four weeks of the study (including while sleeping)
Exclusion Criteria:
- Currently receiving treatment by a therapist or a psychiatrist
- Unstable suicidality (e.g., 2 or more suicide attempts or self-injurious behaviors resulting in hospitalization in the last 6 months)
- Current substance use disorder that interferes with treatment: specifically, patients meeting diagnostic criteria for Substance Use Disorder (SUD) will be eligible for inclusion only if they are able to attend sessions while not under the influence of that substance, with the exception of individuals abusing opiates or freebase cocaine, who will be excluded
- Principal diagnosis of psychosis unrelated to depression (unipolar or bipolar)
- Neurological conditions
- Severe uncontrolled medical conditions (e.g., anorexia nervosa, cardiac conditions requiring continuous monitoring)
- Cognitive impairment (e.g., developmental disability, dementia)
- Previously participated in the UCLA Depression Grand Challenge "New Moms Mood Tracking & Wellbeing Study" (IRB #20-001924)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Tier 2 - PND Digital Therapy with Coaching
Participants with a recent EPDS score in the moderate range (11-18) and no current suicidality will be given access to a perinatal depression online cognitive-behavioral therapy course (the ParentMood program).
Some of the lesson content is presented as illustrated videos.
Following each lesson, participants can download a document that summarizes the key information in each lesson, and which includes practical homework exercises that reinforce the content of the lesson.
Participants are encouraged to practice their lesson homework for at least one week before starting the next lesson.
Lessons will be completed sequentially.
Participants have the option of accessing the content through a web-browser.
Participants may receive up to 9 coaching sessions with their assigned Coach, in addition to an initial Orientation session, which will occur through secure video conference.
The initial Orientation session is required, but the additional coaching sessions thereafter are optional.
|
Participants with a recent EPDS score in the moderate range (11-18) and no current suicidality will be given access to a perinatal depression online cognitive-behavioral therapy course (the ParentMood program).
Some of the lesson content is presented as illustrated videos.
Following each lesson, participants can download a document that summarizes the key information in each lesson, and which includes practical homework exercises that reinforce the content of the lesson.
Participants are encouraged to practice their lesson homework for at least one week before starting the next lesson.
Lessons will be completed sequentially.
Participants have the option of accessing the content through a web-browser.
Participants may receive up to 9 coaching sessions with their assigned Coach, in addition to an initial Orientation session, which will occur through secure video conference.
The initial Orientation session is required, but the additional coaching sessions thereafter are optional.
|
|
Actieve vergelijker: Tier 3 - Clinical Care
Participants with a recent EPDS score in the severe range (19-30) and/or significant suicidality with intent or means will be given access to a clinical care, which entails weekly psychotherapy sessions. The number and schedule of psychotherapy sessions in the study is determined by the clinical care team. Treatment appointments will occur through secure video conference. If the clinical team believes that consultation with a psychiatrist is warranted, a referral will be made to a UCLA Health clinic (e.g., the MOMS Clinic) for a consultation session and possible pharmacotherapy. |
Participants with a recent EPDS score in the severe range (19-30) and/or significant suicidality with intent or means will be given access to a clinical care, which entails weekly psychotherapy sessions.
The number and schedule of psychotherapy sessions in the study is determined by the clinical care team.
Treatment appointments will occur through secure video conference.
If the clinical team believes that consultation with a psychiatrist is warranted, a referral will be made to a UCLA Health clinic (e.g., the MOMS Clinic) for a consultation session and possible pharmacotherapy.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Edinburgh Postnatal Depression Scale (EPDS) total score
Tijdsspanne: From enrollment through the twelve weeks of the study.
|
Self-reported depression symptom severity scores
|
From enrollment through the twelve weeks of the study.
|
|
Percent change in EPDS scores
Tijdsspanne: From enrollment through the twelve weeks of the study.
|
Percent change in self-reported depression symptom severity scores (as measured with EPDS)
|
From enrollment through the twelve weeks of the study.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment retention, as defined by number of coaching or therapy sessions attended by participants
Tijdsspanne: From week 2 through week 13 of the study
|
Measure of treatment retention, as defined by number of coaching or therapy sessions attended.
A participant is considered to have been retained in treatment if they completed number of sessions advised by their therapist, or to have not been categorized as dropping from treatment early.
|
From week 2 through week 13 of the study
|
|
Treatment retention, as defined by whether the participant completed treatment or not
Tijdsspanne: From week 2 through week 13 of the study
|
Measure of treatment retention, as defined by whether the participant completed treatment or not
|
From week 2 through week 13 of the study
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Michelle G Craske, PhD, University of California, Los Angeles
- Hoofdonderzoeker: Nelson Freimer, MD, University of California, Los Angeles
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 25-2121
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .